B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the
investigators anticipate that chronic fatigue syndrome patients may benefit from B-cell
depletion therapy using Rituximab induction with maintenance treatment.
The hypothesis is that at least a subset of CFS patients have an activated immune system
involving B-lymphocytes, and that prolonged B-cell depletion may alleviate symptoms.